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ABSTRACT
The prevalence of pollinosis caused by cedar pollen has increased by 10% these ten years of 26.5% in the in-
vestigation of 2008 in Japan. The pharmacotherapy is a main treatment tool for pollinosis, and the surgical
treatment is not acknowledged to the treatment of pollinosis internationally. Moreover, allergen immunotherapy
enters a special treatment method, and is an important therapeutic procedure. The allergen immunotherapy is
unique for having possibility of curing allergen specific allergic diseases. However the side effect of allergen
subcutaneous immunotherapy (SCIT), such as anaphylaxis is kept at a distance in a medical situation in Japan.
Then, a sublingual immunotherapy (SLIT) that was safer than it, developed in Europe for pollinosis induced by
grass or ragweed, but not in Japan. As a result, the effect of SLIT was proven in the cedar pollinosis in Japan
as high level evidence. A whole body immunity induction is thought in the appearance of the effect, and, in ad-
dition, it is necessary to be going to be cleared the accurate mechanism of the effect in the future. Moreover,
the development of a special SLIT and the import of an overseas product are needed in Japan.
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INTRODUCTION
After Dr Noon begins to appear the conventional al-
lergen specific subcutaneous immunotherapy (SCIT)
in 1911, and is continuing treatment method.1 The ef-
fect of SCIT on pollinosis caused by cedar pollen is
low though the high therapeutic gain is admitted for
the perennial allergic rhinitis in Japan. It is because
the effect of SCIT has decreased relatively because
this depends on the amount of pollen to which the
symptoms of pollinosis and the amount of dispersion
increases in recent years or the administering aller-
gen of SCIT is a little. The problem of anaphylaxis in
cause that SCIT has not become general treatment
though effectiveness is confirmed.2 An alternative im-
munotherapy to change the allergen administering
route in Europe and United States to decrease the
number of side effects of SCIT is done considerably
than before. There are alternative route via the nose,
sublingual, and the oral in the method development
is not done respectively in Japan as for the double
blind test comparison examination though effective-
ness has been proven either. Therefore, it explains
around sublingual immunotherapy (SLIT) that we are
doing without the relation of the pharmaceutical com-
pany in Japan.
DEVELOPMENT IN JAPAN
In SLIT, high effectiveness is shown in Europe, and
the few reports of the anaphylaxis have shown in ran-
domized double blind placebo controlled (RCT) com-
parison examination evaluation.3-5 It was one asthma
case, and it was one diarrhea case in the SLIT 115
cases in three theses. It is recorded that it is not an
anaphylaxis though the asthmatic attack is not de-
scribed detailed. Moreover, that has not arrived im-
portantly though the reaction of one case’s near ana-
phylaxis externals less than ten times of allergen
dose administration was observed by a recent re-
port.6
To receive a lot of these reports, and to make SLIT
adjust to pollinosis caused by cedar pollen from
which the amount of the dispersion pollen was
thought most, the research was started. We did the
ex vivo culture experiment of the first human mouth
mucous membrane incised by the time of surgery for
analysis of allergen aspiration to the mucosal mem-
brane. The double of the amount of the allergen dose
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Table 1 Alergen administration schedule (increasing dosing)
5th week (2000 JAU)4th week (2000 JAU) 3rd week (200 JAU) 2nd week (20 JAU) 1st week (2 JAU) 
20 drops 1 drop 1 drop 1 drop 1 drop1st day
 2 drops 2 drops 2 drops 2 drops2nd day
 4 drops 3 drops 3 drops 3 drops3rd day
 8 drops 4 drops 4 drops 4 drops4th day
20 drops12 drops 6 drops 6 drops 6 drops5th day
18 drops 8 drops 8 drops 8 drops6th day
20 drops10 drops10 drops10 drops7th day
[After sixth week to polen dispersed season, 20 drops of alergen extract was administered once a week sublingualy. After polen dis
persed season, same dose was administered once in two weeks.］
Fig. 1 How to be adapted the alergen extract and bit of 
bread.
in SCIT is almost the same dose aspirated by SLIT.
So SLIT may act as the case of the SCIT is achieved is
guessed by over the double dose of allergen at SCIT.7
HOW TO DO
The approval of the Nippon Medical School ethics
committee was received to the pollinosis caused by
cedar pollen patient and it went from some examina-
tions including this basic experiment in SLIT. The al-
lergen for SLIT, standardized Japanese cedar pollen
allergen (2000 JAU [Japanese Allergology Unit]ml,
Torii Pharmaceutical, Tokyo, Japan), especially for
SCIT products, was used for our SLIT trial. The aller-
gen was able to be put on sublingual by using the bit
of bread for the allergen to flow in actual sublingual
and so as not to go out, then the allergen was kept to
maintain at least for two minutes, and to present the
antigen enough to the lymphatic tissue in the mouth.
The allergen administration was every day accord-
ing the administration schedule from beginning to
the forth week. On the first week, 2 JAU of allergen
was administered from 1 drop to 10 drops, on the sec-
ond week, 20 JAU of allergen was administered from
1 drop to 10 drops, on the third week, 200 JAU of al-
lergen was administered from 1 drop to 10 drops, and
then on forth week 2000 JAU of allergen was adminis-
tered from 1 drop to 20 drops, as the final dose. On
the fifth week twice a week after the sixth week, 2000
JAUml was administered to sublingual 20 drops as
the final highest dose by once a week (Table 1, Fig.
1). There is tablet allergen for SLIT against grass pol-
linosis in Europe. There are some different allergen
characters between Japanese cedar and grass. We
cannot make the tablet allergen for SLIT of Japanese
cedar pollinosis caused by its sticky character now.
THE EFFECT AND THE SIDE EFFECTS
IN JAPANESE CEDAR POLLINOSIS
The Japanese cedar and cypress pollen dispersion
was about 12000 grains, a large amount of dispersion
in 2005 for these ten years. The RCT comparison by
60 cases was examined for making the first evidence
in Japan. The SLIT group was intentionally low total
symptom score (TSS) compared with the placebo
(Fig. 2). This RCT of SLIT has shown to have low-
ered the symptom score more intentionally than the
placebo in late pollen season.8 SLIT had no significant
difference with the drug therapy in the symptom
score in the comparison research with the current
drug therapy. However, the quality of life (QOL)
score evaluated standardized Japanese Rhinitis Qual-
ity of Life Questionnaire (JRQLQ), is significantly de-
creased by SLIT group than placebo group, up to half
level of score. QOL deterioration is significantly in-
hibited by SLIT (Fig. 3).
Moreover, it was confirmed though the side effect
was completely fewer. Itchy of the tongue and the
mouth when the antigen was administered, the feel-
ing of numbness, nasal secretion increases, itchy of
the skin, and hives were admitted at total of fre-
quency of about 10% through the experiment, there
were neither an anaphylaxis nor an asthmatic attack.
HOW TO ACT
The mechanism of the effect manifestation is known
few up to the present time though the immunity in-
duction of the limited part have some role on most of
the effect of SLIT.4 The mechanism of action for SCIT
have been reported by the reduction of the effecter
cells9,10 and the increase of blocking antibody11-14 in
SLIT for JCP
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Fig. 2 Mean change of total nasal symptom score by SLIT and placebo group.
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the conventional theories ten years ago. Recently,
however, it has become widely accepted that SCIT
may modify the T cell response to natural allergen be-
cause of T cell anergy andor immune deviation15-18
and regulatory T cell enhancement.19
For SLIT in particular, allergen administered to the
oral mucosa accumulates in the sub-mandible lymph
node, in which the immune response occurs20 and
peaks at approximately 2 h after administration.21 An
increase in stimulation index (SI) of PBMC at the
early stage of the SLIT shows that the immunity in-
duction of a sublingual allergen was at least caused in
the general reaction.22 It tried to reduce the side ef-
fect by reducing the effect throughout the body com-
pared with past SCIT in SLIT. However, it has been
understood that this result causes a general immu-
nity induction. One more study of SLIT for Japanese
cedar pollinosis was published by Chiba group also
expressed the SLIT controlled the general Cry j-
specific Th2 clone size.23 The regulatory T cell en-
hancement in general by SLIT has reported in some
papers recently.24-26 So SLIT may act on generally,
not just locally. It is necessary to clarify the exact ef-
fect mechanism of SLIT from the examination of the
regional lymph node etc. by a similar examination
that increased the number of cases or a detailed basic
examination on animals in near future.
FOR THE FUTURE IN JAPAN
Approximately 15% of the Japanese population is af-
fected by Japanese cedar pollinosis in 200227 and in-
crease up to 26.5% in 2008.28 The proportion of severe
status patients is higher than with grass or ragweed
pollinosis, which is the representative condition in
other countries. The symptoms of Japanese cedar
pollinosis persist for about 3 months, becoming a so-
cial issue. When the amount of pollen increases, pa-
tients show more severe symptoms, and the number
of severe status patients is greatest in mid-March
when the pollen count reaches its peak. Substantial
antigen exposure enhances the antigen-antibody re-
action in the airways (airway hypersensitivity), which
is the mechanism involved in severe pollinosis, and
immunotherapy with antigen-specific effects may con-
trol the exacerbation of the symptoms in the latter
half of the cedar pollen season by inhibiting antigen-
related enhancement of nasal mucosal hypersensitiv-
ity.
In SCIT for pollinosis treatment, the comments and
responses of WHO are that the effect is verified from
a lot of RCT comparison examinations.29 However, it
is a treatment method to which the medical treatment
of Japan is kept at a distance because of the complex-
ity, the possibility of the side effects, the cost and the
enforcement under the present situation. The drug
therapy is a main current in Japan where the allergy
clinic has not been established from these problems
for pollinosis. However, the immunotherapy that is
fundamental treatment is an important method in the
allergy management. The new SLIT shows the effect
in pollinosis by cedar pollen was clarified in our ex-
amination in Japan. Any QOL fields and items be-
came half QOL deterioration by the placebo in the
evaluation using JRQLQ No1. This QOL question-
naire developed in Japan in the symptom score
though the difference with the placebo was small in
pharmacological treatment.30 SLIT strongly controls
the QOL deterioration in pollinosis rather than the
symptom score to do effect is thought. Of the local
immunotherapy modalities and SLIT is the most ef-
fective with a lower incidence of side effects, which
complies with the WHO position paper on allergen
Okubo K et al.
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Fig. 3 The mean change of QOL score. A), total QOL scores; B), health related 
QOL fields.
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immunotherapy requiring a new route of administra-
tion, such as local immunotherapy, and treatment
that does not cause anaphylaxis, such as peptide ther-
apy.31
In the comparison of double blinds RCT of the im-
munotherapy by a SLIT and the SCIT examination,
the report is still few.32 As for the level of the side ef-
fect frequency and the effect, it is uncertain. The
score of the symptom medicine passes low through
the pollen dispersion all seasons. This shows that the
drug use decreases in SLIT and corresponding to the
result of the RCT examination that uses the pla-
cebo.33 It is thought that the effect equal with the
drug use is shown, and a SLIT from which the use of
the medicine is decreased is useful in economy. In
SLIT studies in Japan, SLIT both inhibited the exacer-
bation of symptoms in the latter half of the season
and reduced their severity throughout the season.
Furthermore, there were neither local nor systemic
side effects, as reported elsewhere for other antigens.
SLIT for cedar pollinosis is a new therapy and in
the future SLIT may by indicated for patients with na-
sal allergy caused by other allergens such as house
dust mites or animal dander through improvement of
the administration schedule and establishing the
dose at which the most potent effects are achieved.
It is the Ministry of Health, Labour and Welfare sci-
ence research expense subsidy immunity and an al-
lergy prevention treatment research grant (H14-
immunity-001), (H17-immunity-general-001), as for
development in this SLIT Japan. It is now progressing
as a multicenter study in “Research of the ideal way
of information on the real-time monitor pollen count
and clinical research on sublingual peptide and the
adjuvant therapy (H20-immunity-general-003)”.
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